ArticleCureus2025
Computed Tomography and Magnetic Resonance Imaging Findings in Early Glioblastoma (e-GBM): Spotting the Wolf in Sheep's Clothing.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Basal ganglia glioblastoma with lung adenocarcinoma tumor-to-tumor metastasis and atypical early imaging presentation: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiological differences exist between early-stage and late-stage glioblastoma (GBM). Most clinicians are aware of the latter appearances, but in our experience, early GBM (e-GBM) is often missed due to the absence of these classical findings. In this retrospective cohort study, we aim to highlight the radiological findings of e-GBM in order to improve recognition. This is important, as earlier recognition and treatment of this serious condition may improve prognosis.
methodsA retrospective study of all patients presented at our institutional neuro-oncology multidisciplinary team meeting between 2012 and 2023 was undertaken. All patients had histologically confirmed GBM and early imaging that did not demonstrate the typical characteristics of malignant tumour. Imaging performed prior to the development of classical magnetic resonance imaging (MRI) features was reviewed by a single experienced neuroradiologist to investigate common imaging characteristics of e-GBM.
resultsThirty-four patients (21 male, 13 female) were included. All patients presented with neurological symptoms and underwent MRI, with 30 of 34 patients having gadolinium-enhanced MRI. On T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, all 34 patients had cortical signal change, while 33 of 34 patients had signal change in the subcortical region. All regions of FLAIR and T2 signal change demonstrated associated restricted diffusion. Thirty-two of 34 patients underwent computed tomography (CT) prior to MRI. Twenty-three of 32 patients had hyperdensity on CT correlating with areas of signal change on MRI.
conclusione-GBM should be considered in patients presenting with neurological symptoms, in particular seizures, when T2WI or FLAIR signal abnormalities in a cortical or subcortical location are seen with associated restricted diffusion. Hyperdensity on non-contrast CT imaging congruent with areas of signal change on MRI should also prompt clinicians to consider e-GBM as a differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.